NIKKEI 225
38,617.15 -303.11 (-0.78%) HANG SENG
19,376.53 0.00 (0.00%) CRUDE OIL
79.21 -0.02 (-0.03%) GOLD FUTURES
2,380.60 -4.90 (-0.21%) DOW
39,869.38 -38.62 (-0.10%) Bitcoin GBP
51,504.45 -756.87 (-1.45%)
Arcus Biosciences, Inc. (RCUS)
After hours:
| Previous close | 17.55 |
| Open | 17.58 |
| Bid | 17.31 x 900 |
| Ask | 18.15 x 800 |
| Day's range | 17.15 - 17.81 |
| 52-week range | 12.95 - 25.47 |
| Volume | |
| Avg. volume | 746,204 |
| Market cap | 1.596B |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif., May 09, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 17 new employees options to purchase a total of 141,100 shares of the Company’s common stock at an exercise price per share of $15.26, which was the closing price on May 8, 2024, and restricte
- Business Wire
Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
HAYWARD, Calif., May 08, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a, AXL and PD-1 – across multiple common cancers.
- Business Wire
Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
HAYWARD, Calif., May 02, 2024--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Bank of America Healthcare Conference in Las Vegas, NV. The fireside chat will take place on Thursday, May 16th, 2024 at 10:00am PT.
